JP2023533658A - 急性呼吸窮迫症候群を治療又は予防する方法 - Google Patents
急性呼吸窮迫症候群を治療又は予防する方法 Download PDFInfo
- Publication number
- JP2023533658A JP2023533658A JP2022574594A JP2022574594A JP2023533658A JP 2023533658 A JP2023533658 A JP 2023533658A JP 2022574594 A JP2022574594 A JP 2022574594A JP 2022574594 A JP2022574594 A JP 2022574594A JP 2023533658 A JP2023533658 A JP 2023533658A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- csf
- subject
- dose
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Storage Of Fruits Or Vegetables (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020901843 | 2020-06-04 | ||
| AU2020901843A AU2020901843A0 (en) | 2020-06-04 | Method of treating or preventing acute respiratory distress syndrome | |
| PCT/AU2021/050568 WO2021243424A1 (en) | 2020-06-04 | 2021-06-07 | Method of treating or preventing acute respiratory distress syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533658A true JP2023533658A (ja) | 2023-08-04 |
| JP2023533658A5 JP2023533658A5 (cg-RX-API-DMAC7.html) | 2024-06-12 |
Family
ID=78830044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574594A Pending JP2023533658A (ja) | 2020-06-04 | 2021-06-07 | 急性呼吸窮迫症候群を治療又は予防する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12583929B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4161576A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023533658A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240008231A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115768475A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021285088A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3175686A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021243424A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024003788A1 (en) * | 2022-06-29 | 2024-01-04 | Novocure Gmbh | Treating acute respiratory distress syndrome with alternating electric fields |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010500291A (ja) * | 2006-08-11 | 2010-01-07 | シーエスエル、リミテッド | 肺疾患病態の処理 |
| JP2014519517A (ja) * | 2011-06-13 | 2014-08-14 | シーエスエル、リミテッド | G−csfrに対する抗体およびその使用 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IE66494B1 (en) | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| AU3691093A (en) | 1992-04-14 | 1993-10-21 | Hybritech Incorporated | Methods of inhibiting the growth of multidrug resistant tumors |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| CA2145278C (en) | 1992-09-25 | 2009-03-10 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
| AUPM375194A0 (en) | 1994-02-08 | 1994-03-03 | Ludwig Institute For Cancer Research | Cytokine receptor interactive molecules |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| ATE374248T1 (de) | 1996-06-27 | 2007-10-15 | Vlaams Interuniv Inst Biotech | Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| CN101818145A (zh) | 1998-03-20 | 2010-09-01 | 联邦科学和工业研究组织 | 控制基因表达 |
| DK1068311T3 (da) | 1998-04-08 | 2011-08-08 | Commw Scient Ind Res Org | Fremgangsmåder og midler til opnåelse af modificerede fænotyper |
| ATE370961T1 (de) | 1998-05-06 | 2007-09-15 | Genentech Inc | Reinigung von antikörpern durch ionenaustauschchromatographie |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| JP2000319298A (ja) | 1999-03-04 | 2000-11-21 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | 蛋白質複合体の結晶、構造座標、及び構造座標の使用 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
| AUPR544401A0 (en) | 2001-06-04 | 2001-06-28 | Bischof, Robert Juergen | Animal model for allergy |
| US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| AU2004245038A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
| CA2531238C (en) | 2003-07-04 | 2015-02-24 | Affibody Ab | Polypeptides having binding affinity for her2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| BRPI0417302A (pt) | 2003-12-05 | 2007-03-06 | Compound Therapeutics Inc | inibidores de receptores de fator de crescimento endotelial vascular do tipo 2 |
| DK1751181T3 (da) | 2004-06-02 | 2012-11-26 | Adalta Pty Ltd | BINDINGSDELE, DER ER BASERET PÅ HAJ IgNAR-DOMÆNER |
| JP4958555B2 (ja) | 2004-09-22 | 2012-06-20 | 協和発酵キリン株式会社 | 安定化されたヒトIgG4抗体 |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2007025166A2 (en) | 2005-08-25 | 2007-03-01 | Repair Technologies, Inc. | Devices, compositions and methods for the protection and repair of cells and tissues |
| CA2654894A1 (en) | 2006-07-06 | 2008-10-01 | Laboratoires Serono S.A. | Csf3r polypeptides and uses thereof |
| US20080199426A1 (en) | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
| CL2008002782A1 (es) | 2007-09-21 | 2009-07-31 | Genentech Inc | Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular. |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| JP2012515556A (ja) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法 |
| FR2950381B1 (fr) | 2009-09-18 | 2011-10-28 | Snecma | Turbomachine a helices non carenees contrarotatives |
| US8968731B2 (en) | 2009-10-09 | 2015-03-03 | Csl Limited | Treatment of uveitis |
| AU2010311332B2 (en) | 2009-10-30 | 2015-04-23 | Albumedix Ltd. | Albumin variants |
| WO2011103076A1 (en) | 2010-02-16 | 2011-08-25 | Medlmmune, Llc | Hsa-related compositions and methods of use |
| EP2367000A1 (en) | 2010-03-04 | 2011-09-21 | Charité Universitätsmedizin Berlin | High throughput analysis of T-cell receptor repertoires |
| CN102869777B (zh) | 2010-04-02 | 2018-11-02 | 库尔纳公司 | 通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病 |
| AU2011319746B2 (en) | 2010-10-27 | 2015-07-30 | Celldex Therapeutics, Inc. | Method of improving transplant function using soluble complement receptor type I (sCR1) |
| EP2675471A4 (en) | 2011-02-15 | 2015-01-28 | Medimmune Llc | HSA-RELATED COMPOSITIONS AND USE PROCESSES |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| US9050305B2 (en) | 2012-03-29 | 2015-06-09 | Chs Pharma, Inc. | Treatment for ischemic stroke |
| CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2014179657A1 (en) | 2013-05-03 | 2014-11-06 | Eleven Biotherapeutics, Inc. | Albumin variants binding to fcrn |
| EP3063171B1 (en) | 2013-11-01 | 2019-07-24 | University Of Oslo | Albumin variants and uses thereof |
| JP2017507939A (ja) | 2014-02-21 | 2017-03-23 | ジェネンテック, インコーポレイテッド | 抗il−13/il−17二重特異性抗体及びその使用 |
| EP3220952B1 (en) | 2014-11-17 | 2021-04-21 | CSL Limited | Method of treating or preventing stroke |
| EP3445450A4 (en) | 2016-04-21 | 2020-01-08 | CSL Limited | METHOD FOR TREATING OR PREVENTING LIVER DISEASES |
| US20210179721A1 (en) | 2017-11-29 | 2021-06-17 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
| KR20190073917A (ko) * | 2017-12-19 | 2019-06-27 | 포항공과대학교 산학협력단 | 인터류킨-17 억제제 및 종양괴사인자-알파 억제제를 유효성분으로 포함하는 호중구성 폐 염증질환의 예방 또는 치료용 약학적 조성물 |
| US12281160B2 (en) * | 2018-03-23 | 2025-04-22 | Csl Limited | Method of treating asthma |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| JP7503056B6 (ja) | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗lag3抗体および抗pd-1抗体の共-製剤 |
| BR112021010920A2 (pt) * | 2018-12-04 | 2021-08-31 | CSL Innovation Pty Ltd | Método de tratamento de condições neutrofílicas |
| KR20220019806A (ko) * | 2019-06-12 | 2022-02-17 | 씨에스엘 이노베이션 피티와이 엘티디 | 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도 |
| US20240002517A1 (en) * | 2020-12-16 | 2024-01-04 | CSL Innovation Pty Ltd | Protein formulations and uses thereof |
-
2021
- 2021-06-07 CN CN202180036037.8A patent/CN115768475A/zh active Pending
- 2021-06-07 US US18/000,153 patent/US12583929B2/en active Active
- 2021-06-07 CA CA3175686A patent/CA3175686A1/en active Pending
- 2021-06-07 KR KR1020227046116A patent/KR20240008231A/ko active Pending
- 2021-06-07 AU AU2021285088A patent/AU2021285088A1/en active Pending
- 2021-06-07 WO PCT/AU2021/050568 patent/WO2021243424A1/en not_active Ceased
- 2021-06-07 EP EP21818292.1A patent/EP4161576A4/en active Pending
- 2021-06-07 JP JP2022574594A patent/JP2023533658A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010500291A (ja) * | 2006-08-11 | 2010-01-07 | シーエスエル、リミテッド | 肺疾患病態の処理 |
| JP2014519517A (ja) * | 2011-06-13 | 2014-08-14 | シーエスエル、リミテッド | G−csfrに対する抗体およびその使用 |
Non-Patent Citations (3)
| Title |
|---|
| EXPERT REVIEW OF RESPIRATORY MEDICINE, vol. Vol. 4, Issue 6, JPN6025024355, 2014, pages 773 - 783, ISSN: 0005817605 * |
| JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. Vol.23, Issue 12, JPN6025024353, 2003, pages 729 - 736, ISSN: 0005817607 * |
| SCIENCE TRANSLATIONAL MEDICINE, vol. Vol.7, Issue 278, JPN6025024354, 2015, pages 278 - 32, ISSN: 0005817606 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230272087A1 (en) | 2023-08-31 |
| CN115768475A (zh) | 2023-03-07 |
| US12583929B2 (en) | 2026-03-24 |
| AU2021285088A1 (en) | 2023-01-05 |
| CA3175686A1 (en) | 2021-12-09 |
| WO2021243424A1 (en) | 2021-12-09 |
| KR20240008231A (ko) | 2024-01-18 |
| EP4161576A1 (en) | 2023-04-12 |
| EP4161576A4 (en) | 2024-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11866503B2 (en) | Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor | |
| JP2023052457A (ja) | Il-4rアンタゴニストを投与することにより喘息を処置又は予防するための方法 | |
| CN111108118A (zh) | 用C5a活性抑制剂治疗炎性疾病 | |
| JP7570328B2 (ja) | 好中球性病態の治療方法 | |
| JP6553075B2 (ja) | さらなるccr3−結合ケモカインを認識する抗エオタキシン−2抗体 | |
| US12281160B2 (en) | Method of treating asthma | |
| US20230279129A1 (en) | Method of treating or preventing ischemia-reperfusion injury | |
| KR102558891B1 (ko) | 항―il4―il13 2특이성 항체 | |
| US12583929B2 (en) | Method of treating acute respiratory distress syndrome | |
| US20230416381A1 (en) | Methods for treating or preventing acute respiratory distress syndrome | |
| US12357689B2 (en) | Methods of treating or preventing a cardiovascular system complication of sickle cell disease with an anti-G-CSFR antibody | |
| JP7216157B2 (ja) | Il-4rアンタゴニストを投与することにより喘息を処置又は予防するための方法 | |
| WO2025217677A1 (en) | Methods for treating neutrophilic skin conditions | |
| CN117062609A (zh) | 用于治疗或预防急性呼吸窘迫综合征的方法 | |
| WO2025217678A1 (en) | Methods of treating or delaying progression or hindering development of a neutrophil-associated condition | |
| HK40035988A (en) | Method of treating or preventing ischemia-reperfusion injury | |
| HK40035988B (en) | Method of treating or preventing ischemia-reperfusion injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240604 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240604 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250617 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250910 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260317 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260529 |